Exclusive Summary

• Disruptive compliance advantage: An expected ultra-long-acting formulation administered subcutaneously every 3 to 6 months, significantly superior to standard daily or monthly regimens, thereby drastically improving regimen adherence for elderly chronic patients.
• Exceptional efficacy driven by first-in-class synergistic mechanism: The single-molecule bi-functional fusion protein simultaneously inhibits RANKL-driven bone resorption and promotes PTH-mediated new bone formation, demonstrating robust and sustained bone mineral density (BMD) improvement in OP monkey models, outperforming the blockbuster Denosumab.
• Maximized safety profile mitigating black-box risks: Through targeted engineering, conditionally activated PTH maintains its physiological activity in bone tissue while demonstrating a greater than 100-fold reduction in renal activity, thereby evading cardiovascular MACE events and hypercalcemia associated with current options like Romosozumab and Teriparatide.
• Highly attractive asset for global partnership: Currently in the IND-enabling phase, UB706 offers multinational pharmaceutical companies an optimal early-intervention window, serving as ideal pipeline material for strategic global license-out or co-development in endocrinology and orthopedics.

Asset Materials

Contact Us for Full Materials